During the past decade, Emory Eye Center conducted 27 clinical trials. In the 10-year time frame, 27 clinical trials started and 16 clinical trials were completed, i.e. on average, 59.3% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 12 clinical trials were completed. i.e. 109.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Emory Eye Center" #1 sponsor was "Jaeb Center for Health Research" with 13 trials, followed by "National Eye Institute (NEI)" with 6 trials sponsored, "Emory University" with 4 trials sponsored, "Allergan" with 2 trials sponsored and "Clearside Biomedical, Inc." with 2 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Emory Eye Center" #1 collaborator was "National Eye Institute (NEI)" with 15 trials as a collaborator, "Pediatric Eye Disease Investigator Group" with 5 trials as a collaborator, "Regeneron Pharmaceuticals" with 4 trials as a collaborator, "National Institutes of Health (NIH)" with 3 trials as a collaborator and "Foundation Fighting Blindness" with 2 trials as a collaborator. Other collaborators include 41 different institutions and companies that were collaborators in the rest 48 trials.

According to Clinical.Site data, the most researched conditions in "Emory Eye Center" are "Retinopathy of Prematurity" (5 trials), "Cytomegalovirus Retinitis" (4 trials), "Diabetic Macular Edema" (4 trials), "HIV Infections" (4 trials) and "Retinitis Pigmentosa" (4 trials). Many other conditions were trialed in "Emory Eye Center" in a lesser frequency.

Most popular intervention types in "Emory Eye Center" are "Drug" (36 trials), "Procedure" (9 trials), "Device" (7 trials), "Other" (7 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Bevacizumab" (5 trials), "Placebo" (4 trials), "Ganciclovir" (3 trials), "Bimatoprost SR" (2 trials) and "Deferred aflibercept" (2 trials). Other intervention names were less common.

The vast majority of trials in "Emory Eye Center" are 54 trials for "All" genders.

Currently, there are 11 active trials in "Emory Eye Center". 1 are not yet recruiting, 6 are recruiting, 3 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 32 completed trials in Emory Eye Center, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Emory Eye Center, 3 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 31 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 7 trials that are defined as “Not Applicable".